Scarica l'app Stockscreener
5.69
2.23%
-0.13
Dopo l'orario di chiusura:
5.69
Precedente Chiudi:
$5.82
Aprire:
$5.73
Volume 24 ore:
880.51K
Relative Volume:
0.70
Capitalizzazione di mercato:
$492.64M
Reddito:
-
Utile/perdita netta:
$-168.09M
Rapporto P/E:
-2.6221
EPS:
-2.17
Flusso di cassa netto:
$-138.01M
1 W Prestazione:
+0.89%
1M Prestazione:
-12.73%
6M Prestazione:
-48.46%
1 anno Prestazione:
-72.50%
Intervallo 1D:
$5.53
$5.74
Intervallo di 1 settimana:
$5.48
$5.84
Portata 52W:
$5.41
$23.48
Kura Oncology Inc Stock (KURA) Company Profile
Nome
Kura Oncology Inc
Settore
Industria
Telefono
(858) 500-8800
Indirizzo
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Confronta KURA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
5.69 | 488.28M | 0 | -168.09M | -138.01M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-06 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-14 | Downgrade | Stifel | Buy → Hold |
| 2023-12-22 | Iniziato | Mizuho | Buy |
| 2023-08-11 | Iniziato | BofA Securities | Buy |
| 2023-07-27 | Iniziato | Scotiabank | Sector Perform |
| 2023-05-17 | Iniziato | BTIG Research | Buy |
| 2023-01-31 | Iniziato | Stifel | Buy |
| 2022-07-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-02-15 | Iniziato | Jefferies | Buy |
| 2021-05-05 | Ripresa | Credit Suisse | Outperform |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2020-12-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-03 | Iniziato | Stifel | Buy |
| 2020-11-05 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-07-07 | Iniziato | Credit Suisse | Outperform |
| 2020-05-05 | Iniziato | Barclays | Overweight |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-11-09 | Iniziato | Piper Jaffray | Overweight |
| 2018-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2016-10-13 | Ripresa | Leerink Partners | Outperform |
| 2016-01-22 | Iniziato | JMP Securities | Mkt Outperform |
| 2015-12-30 | Iniziato | Oppenheimer | Outperform |
| 2015-12-16 | Iniziato | Citigroup | Buy |
Mostra tutto
Kura Oncology Inc Borsa (KURA) Ultime notizie
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Buys 21,135 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Kura Oncology’s SWOT analysis: ziftomenib success key to stock’s future By Investing.com - Investing.com South Africa
Kura Oncology’s SWOT analysis: ziftomenib success key to stock’s future - Investing.com
Kura Oncology (NASDAQ:KURA) Trading Down 4.7% – Time to Sell? - Defense World
Cantor Fitzgerald maintains Overweight on Kura Oncology stock - Investing.com Australia
Cantor Fitzgerald maintains Overweight on Kura Oncology stock By Investing.com - Investing.com South Africa
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - MSN
Jane Street Group LLC Sells 25,869 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology to present trial results for AML treatment - Investing.com Australia
Kura Oncology to present trial results for AML treatment By Investing.com - Investing.com Nigeria
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Announce KOMET-001 Trial Results for Ziftomenib in R/R NPM1-m AML Selected for ASCO Presentation - Nasdaq
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting - The Manila Times
Northern Trust Corp Sells 20,239 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology to Participate in Three Upcoming Investor Conferen - GuruFocus
Kura Oncology to Participate in Three Upcoming Investor Conferences - The Manila Times
Kura Oncology, Inc. to Participate in Upcoming Investor Conferences in May and June 2025 - Nasdaq
Kura Oncology Sets Triple Conference Schedule: Goldman Sachs, Jefferies, and TD Cowen Healthcare Events - Stock Titan
Kura Oncology (NASDAQ:KURA) Price Target Lowered to $30.00 at Mizuho - Defense World
KURA: Mizuho Maintains Rating but Lowers Price Target for Kura O - GuruFocus
Kura Oncology (KURA) Target Price Adjusted by Mizuho | KURA Stoc - GuruFocus
Balyasny Asset Management L.P. Has $144,000 Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Stock Position Raised by BNP Paribas Financial Markets - Defense World
Price T Rowe Associates Inc. MD Raises Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Mizuho Adjusts Price Target on Kura Oncology to $30 From $32, Maintains Outperform Rating - marketscreener.com
How To Trade (KURA) - news.stocktradersdaily.com
Kura Oncology (KURA) to Present Promising AML Treatment Data at 2025 EHA Congress | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Announce Combination Data for Zift - GuruFocus
Kura Oncology and Kyowa Kirin Announce Combination Data for Ziftomenib in Oral Presentation at the 2025 European Hematology Association (EHA) Congress - The Manila Times
Kura Oncology and Kyowa Kirin to Present Updated Data on Ziftomenib in Combination with 7+3 for AML at EHA2025 Congress - Nasdaq
Kura Oncology Inc (NASDAQ: KURA) – Analysts’ Revisions Point To Positive Sentiment - Stocksregister
Kura Oncology’s Promising Market Position and Growth Prospects Justify Buy Rating - TipRanks
Voya Investment Management LLC Decreases Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Transcript : Kura Oncology, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 03 - marketscreener.com
Dimensional Fund Advisors LP Buys 372,196 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Analysts Just Shipped A Captivating Upgrade To Their Kura Oncology, Inc. (NASDAQ:KURA) Estimates - simplywall.st
Wells Fargo & Company MN Acquires 11,427 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Canada
MetLife Investment Management LLC Purchases 2,776 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com Australia
Kura Oncology to Participate in Bank of America Securities Healt - GuruFocus
KURA Stock Set for Competitive Landscape in Menin Inhibitor Mark - GuruFocus
Kura Oncology to Participate in Bank of America Securities Healthcare Conference - The Manila Times
Kura Oncology CEO Sets Stage for Major Updates at BofA Healthcare Conference Next Week - Stock Titan
Kura Oncology Inc Azioni (KURA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):